<![CDATA[How CELMoDs’ Milder GI AEs May Reduce Discontinuation Rates in Multiple Myeloma]]>

CELMoDsIMiDsPositive

AI Analysis

Summary

Dr. Muhamed Baljevic and Dr. Paul Richardson discuss how CELMoDs may reduce gastrointestinal and neutropenic adverse events associated with IMiDs in multiple myeloma, potentially extending treatment duration and progression-free survival.

Importance:3/10

Sentiment:

0.30

multiple myelomagastrointestinal adverse eventstreatment tolerabilityCELMoDsexpert discussion

Related Companies

$CELG

Read the original article

Published by Cancer Network on July 5, 2026 2:00 PM

Read Original